Altimmune, Inc. (ALT) Q2 2026 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good morning, ladies and gentlemen. Welcome to the Altimmune Second Quarter twenty twenty six Financial Results Conference Call. At this time, all participants are in a listen only mode. After the speakers' presentation, there will be a question and answer session. As a reminder, this call is being recorded. I now introduce your host for today's conference call, Luis Tsunek, Vice President of Investor Relations. Luis, you may begin. Thank you, operator, and good morning, everyone. Thank you for joining us for Altimmune's second quarter twenty twenty six financial results and business update call. On today's call, you will hear from Jerry Durso, our Chairman and Chief Executive Officer, Doctor. Christophe Arvindengels, Chief Medical Officer, Linda Richardson, Chief Commercial Officer, and Greg Weaver, Chief Financial Officer. Following management's prepared remarks, we'll open the line for questions. Our second quarter twenty twenty six earnings release was issued this morning and can be found in the Investor Relations section of our website. Before we begin, I would like to remind everyone that remarks made about future expectations, plans, and prospects constitute forward looking statements for the purpose of safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Altimmune cautions that these forward looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those indicated. For a review of the risk factors that could affect the company's future results and operations, we refer you to our SEC filings. I also direct you to read the forward looking statements disclaimer in our press release issued this morning. Any statements made on this call speak only as of today's date, 08/12/2026...